Genetic Engineering of Immune Evasive Stem Cell-Derived Islets

Sara D. Sackett, Samuel J. Kaplan, Samantha A. Mitchell, Matthew E. Brown, Adam L. Burrack, Shane Grey, Danwei Huangfu, Jon Odorico

Research output: Contribution to journalReview articlepeer-review

6 Scopus citations


Genome editing has the potential to revolutionize many investigative and therapeutic strategies in biology and medicine. In the field of regenerative medicine, one of the leading applications of genome engineering technology is the generation of immune evasive pluripotent stem cell-derived somatic cells for transplantation. In particular, as more functional and therapeutically relevant human pluripotent stem cell-derived islets (SCDI) are produced in many labs and studied in clinical trials, there is keen interest in studying the immunogenicity of these cells and modulating allogeneic and autoimmune immune responses for therapeutic benefit. Significant experimental work has already suggested that elimination of Human Leukocytes Antigen (HLA) expression and overexpression of immunomodulatory genes can impact survival of a variety of pluripotent stem cell-derived somatic cell types. Limited work published to date focuses on stem cell-derived islets and work in a number of labs is ongoing. Rapid progress is occurring in the genome editing of human pluripotent stem cells and their progeny focused on evading destruction by the immune system in transplantation models, and while much research is still needed, there is no doubt the combined technologies of genome editing and stem cell therapy will profoundly impact transplantation medicine in the future.

Original languageEnglish (US)
Article number10817
JournalTransplant International
StatePublished - Dec 5 2022

Bibliographical note

Funding Information:
This work was supported by grants from the Juvenile Diabetes Research Foundation (3-SRA-2021-1060-S-B) and the Department of Defense (W81XWH2010669, W81XWH2010670) to JO and DH, and an NIH Training Grant (T32GM008539) to SJK. This work was supported in part by the Wisconsin Alumni Research Foundation, NIH NIAID 75N93021C00004, NIH NHLBI U01HL134764, NIH NIDDK R01DK096239.

Publisher Copyright:
Copyright © 2022 Sackett, Kaplan, Mitchell, Brown, Burrack, Grey, Huangfu and Odorico.


  • HLA allobarrier
  • allograft rejection
  • regenerative medicine
  • type I diabetes


Dive into the research topics of 'Genetic Engineering of Immune Evasive Stem Cell-Derived Islets'. Together they form a unique fingerprint.

Cite this